Form 4 for CAI Caris Life Sciences, Inc.
Accepted 2026-01-13 00:00:00 ET · period of report 2026-01-09 · accession 0001239594-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-13 | 2026-01-09 | CAI | CASTLEMAN PETER M | Dir | M - OptEx | $18.60 | +2,500 | 18.6K | +16% | +$46.5K |
| D | 2026-01-13 | 2026-01-09 | CAI | CASTLEMAN PETER M | Dir | M - OptEx | $0.00 | -2,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-09 | M | A | 2,500 | $18.60 | 18,629 | D | — | — | |
| 2 | Derivative | Stock Option | 2026-01-09 | M | D | 2,500 | $0.00 | 0 | D | $18.60 · — to 2035-02-27 | 2,500 Common Stock | (F2) The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3. |